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a  b  s  t  r  a  c  t
The Psychosocial Care Center (CAPS) is a community-based mental health service in Brazil,
which aims to promote the psychosocial rehabilitation of patients. Accordingly, this study
describes the drug use evaluation in a primary mental health service in Northeast of Brazil.
Setting: CAPS ‘Valter Correia’, São Cristovão, Sergipe, Brazil.
Methods: A cross-sectional study was conducted between August 2009 and May 2010. Ini-
tially, Medical records were reviewed and evaluated. Then, we applied interviews with the
patients (and/or their informal/family caregivers) attended at the CAPS. Informations were
obtained regarding to demographic and clinical features, diagnoses and drugs prescribed.
All  patients registered in the CAPS were included in the study. The results were statistically
analyzed using the EpiInfo and were compared with results from literature.
Results: The CAPS ‘Valter Correia’ consists of 101 registered patients, the majority were male
(58.4%), illiterate (51.5%), without monthly income (49.5%) and the average age of them 42.2
years  (SD = 12.0). Schizophrenia was the most frequent mental disorder (31.5%). The average
number of medications by patients was 3.11 (SD = 1.41), and the older group of patients
(75-80 years) presented the largest consumption of medications (5.50 drugs/patient). The
psychiatric drug class most frequently prescribed was antipsychotics (44.8%). Angiotensin-
converting enzyme inhibitors were the most prevalent non-psychiatric therapeutic class
(15.8%). It was detected 133 drug-drug interactions (3.0% mild, 54.1% moderate, 29.3% severeand  13.5% contraindicated).Conclusion: The results revealed the need for monitoring the pharmacotherapy of patients
with  mental disorders to encourage the rational use of medications.
© 2011 Escola Nacional de Saúde Pública. Published by Elsevier España, S.L. All rights
reserved.
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Estudo  de  utilizac¸ão  de  medicamentos  em  um  servic¸o de  saúde  mental
primário  no  Nordeste  do  Brasil
Palavras chave:
Centro de Atenc¸ão Psicossocial
Estudo de Utilizac¸ão
de medicamentos
Saúde Mental
R  e  s  u  m  o
O Centro de Atenc¸ão Psicossocial (CAPS) é um servic¸o de saúde mental de base comunitária
no  Brasil, que visa promover a reabilitac¸ão psicossocial dos pacientes. O presente estudo
descreve a avaliac¸ão do uso de medicamentos em um service de saúde mental primário no
Nordeste do Brasil.
Ambiente: CAPS «Valter Correia»,  São Cristovão, Sergipe, Brasil.
Métodos: Estudo transversal foi realizado entre agosto de 2009 e maio de 2010. Inicialmente,
os  registros médicos foram revisados e avaliados. Em seguida, foram realizadas entrevistas
com os pacientes (e/ou seus cuidadores) atendidos no CAPS. Informac¸ões foram obtidas
sobre as características demográﬁcas e clínicas, diagnósticos e medicamentos prescritos.
Todos os pacientes cadastrados no CAPS foram incluídos no estudo. Os resultados foram
analisados estatisticamente utilizando o programa EpiInfo e foram comparados com os
resultados da literatura.
Resultados: O CAPS “Valter Correia” é composto por 101 pacientes cadastrados, a maioria do
sexo masculino (58,4%), analfabetos (51,5%), sem renda mensal (49,5%) e a média de idade
deles era de 42,2 anos (DP = 12,0). A esquizofrenia foi o transtorno mental mais freqüente
(31,5%). O número médio de medicamentos por pacientes foi de 3,11 (DP = 1,41), e o grupo
de  pacientes mais velhos (75-80 anos) apresentou o maior consumo de medicamentos (5,50
medicamentos/paciente). A classe de medicamentos psiquiátricos mais prescrita foi a dos
antipsicóticos (44,8%). A classe dos inibidores da enzima conversora da angiotensina foi a
mais prevalente classe não-psiquiátrica (15,8%). Foram detectadas 133 interac¸ões medica-
mentosas fármaco-fármaco (3,0% de severidade leve, 54,1% moderada, 29,3% grave e 13,5%
contra-indicada).
Conclusão: Os resultados demonstram a necessidade de acompanhamento da farmacoter-
apia de pacientes com transtornos mentais para incentivar o uso racional de medicamentos.
©  2011 Escola Nacional de Saúde Pública. Publicado por Elsevier España, S.L. Todos osIntroduction
Mental disorders represent a health problem of social rele-
vance for their high incidence in populations from different
countries and culturally distinct societies. We estimated
17–35% prevalence of mental disorders in Brazilian popula-
tion. However, these disorders are still far from receiving an
adequate importance.1–4
In this context, the introduction of psychosocial care cen-
ters (CAPS) were one of some health services created, based on
Brazilian psychiatric reform. The CAPS are characterized by a
day care service, which is proposed as an alternative to a psy-
chiatric hospital. Its main objective is to offer a psychosocial
rehabilitation to their patients.5
The sociodemographic characteristics of CAPS patients
have an important inﬂuence to improve their assistance.2,6
Moreover, psychotropic drugs cause adverse events, which
compromises the adherence to treatment and then the quality
of life.7
Some studies have demonstrated the relationship between
the process of use of drugs, morbidity and mortality related
to drugs and as these may trigger adverse reactions. In these
studies, problems such as adverse reactions, non-compliance,
overdose or inadequate therapy are factors that lead to failure
of therapy. If this is not detected and resolved, it can lead to
death.8–15direitos reservados.
Thus, it is necessary to evaluate the drug utilization in men-
tal health care in order to assess drug therapy, detect the risk
factors associated with the use of medications and promote
the rational use of drugs. Drug utilization research are deﬁned,
according to WHO,  as studies on marketing, distribution, pre-
scription, and use of drugs in a society, with special emphasis
on the resulting medical, social and economic consequences.
These studies have as their main objective the promotion of
the rational use of drugs.16,17
In recent years, literature has highlighted the involve-
ment of the pharmacist in programs to optimize the effects
of medications, through monitoring the use of drugs. The
application of rational criteria can ensure greater compliance
with therapy, effectiveness and safety of medications used by
patients.18–20
Aim  of  study
The present study aimed to evaluate the use of medications
by patients in a primary mental health service located in a city
at the Northeast of Brazil.Methods
We conducted, in an unprecedented way in Sergipe state, a
cross-sectional study between August 2009 and May 2010 at a
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Table 1 – Sociodemographics data of patients attended at
CAPS Valter Correia (n = 101).
Variables AF (RF%)*
Gender
Male 59 (58.40)
Female 42 (41.60)
Educational status
Analphabet 52 (51.50)
Uncompleted primary school 36 (35.60)
Primary school 1 (0.99)
Uncompleted secondary school 8 (7.90)
Secondary school 4 (3.96)
Occupational activity
None 91 (90.10)
Housemaid 1 (0.99)
Homemaker 4 (3.96)
Bricklayer 2 (1.98)
Fishman 3 (2.97)
Beneﬁt/pensions
Receive 51 (50.50)
No receive 50 (49.50)
Income (monthly)
No income 50 (49.50)
1 minimum wage ($ 28,736) 49 (48.50)
2 minimum wage ($ 57,471) 1 (0.99)
3 minimum wage ($ 86,207) 1 (0.99)
Marital status
Single 77 (76.20)
Married or living as married 17 (16.80)
Divorced 2 (1.98)
Widowed 5 (4.95)
∗ AF – Absolute frequency, RF% – Relative frequency in percentage.r e v p o r t s a ú d e p ú b
ype I psychosocial care center (CAPS) ‘Valter Correia’ in São
ristovão, Sergipe, Brazil. All patients registered in the CAPS
and/or their informal/family caregivers) were included in the
tudy.
CAPS type I is a unit for own psychosocial care with
herapeutic workshops and other forms of care and opera-
ional capacity to provide healthcare coverage to a population
etween 20,000 and 70,000 inhabitants, working under two
hifts, developing daily activities in mental health.21
Data was collected from patient medical records, such
s sociodemographics, clinical characteristics and pharmaco-
ogical treatments. Sociodemographic data included patient
ender, age, educational status, occupational activity, beneﬁts
r pensions, income and marital status. Diagnoses (accord-
ng to the ICD-10 international classiﬁcation of mental and
ehavioral disorders)22 and the patient’s psychiatric admis-
ion history were the clinical characteristics obtained. Details
f all psychiatric prescribed medications were also collected,
ncluding dose, frequency, administration routes and ther-
peutic indications. Drugs were classiﬁed according to the
natomical therapeutic chemical (ATC) classiﬁcation system
nd the deﬁned daily dose (DDD). The ATC/DDD system is a
idely used tool for exchanging and comparing data on drug
onsumption at international, national or local levels.23
In addition, personal interviews were performed (applied to
he patients and/or their informal/family caregivers) and col-
ective interviews (applied to groups of patients and/or their
nformal/family caregivers), in order to compare informations
egistered on records, collect the missing data on records,
dentify features on the use of medications and characterize
he perception of patients about their health problems and
heir treatments. The interviews were conducted by a gradu-
te student in pharmacy, previously trained.
The protocols were approved by the Ethics Committee on
uman Research at the Federal University of Sergipe. Patients
articipating in the study were informed about every step and
greed to participate in the survey through a term of informed
onsent.
The programs EPI-INFO (version 3.5.1-obtained from
ww.cdc.gov/EpiInfo) and Excel (Microsoft®) were used to sta-
istical analysis. The study protocol was approved by the Ethics
ommittee of Federal University of Sergipe.
During the development of this study, it was ministered
ectures, home visits, workshops and meetings for patients,
nformal/family caregivers, and for the multidisciplinary team
f the CAPS. The themes approached the rational use of
edications, mental disorder, psychopharmacology, medic-
nal plants, hygiene, handicraft, culture, integration, social
nclusion, ﬁrst aid and use of alcohol, tobacco and others
rugs.
esults
01 registered patients were distributed in intensive (13.86%),
emi-intensive (52.48%) and non-intensive (33.66%) regime at
APS Valter Correia. Those regimes are deﬁned by their clini-
al conditions, based on clinical care and therapy of patients.
ccording to their needs, patients belonging to intensive
egime require daily care by a specialized multidisciplinaryteam (up to 25 days/month), patients belonging to semi-
intensive regime require frequent care (up to 12 days/month)
and patients belonging to non-intensive regime require less
frequent attendance (up to 3 days of the month).
The mean age of patients was 42.18 ± 12.01-years-old,
median of 42 years. Table 1 describes the distribution of other
important socio-demographic parameters.
Schizophrenia was the most prevalent mental disorder
(31.53%). The mental disorder proﬁle presented by the patients
attended on the CAPS, according with the international clas-
siﬁcation of mental and behavioral disorders (ICD-10)22 is
described in Table 2.
Some patients presented other diseases associated to men-
tal disorders, such as arterial hypertension (18.81%), diabetes
mellitus (10.9%), gastritis (10.9%), asthma (4.0%), others heart
problems (7.9%) and hypothyroidism (2.2%).
Regarding to the pharmacotherapeutic proﬁle, Table 3
exhibits the therapeutic classes of psychiatric drugs used
by patients attended at CAPS. Table 4 describes the the-
rapeutic classes of non-psychiatric drugs used by patients
attended at CAPS, according to the WHO-ATC/DDD method-
ology. The psychiatric drug class most frequently prescribed
was antipsychotics (44.8%) and the non-psychiatric drug class
most prevalent was angiotensin-converting enzyme inhibitors
(15.8%).
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Table 2 – Mental disorders diagnosed at CAPS patients
according to ICD-10 (n = 101).
ICD Mental disorders AF (RF%)a
F06 Other mental disorders due
to brain damage and dysfunction
and to physical disease
5  (4.50)
F10 Mental and behavioural disorders
due to use of alcohol
20 (18.02)
F20 Schizophrenia 35 (31.53)
F21 Schizotypal disorder 3 (2.70)
F25 Schizoaffective disorders 3 (2.70)
F29 Unspeciﬁed nonorganic psychosis 8 (7.21)
F31 Bipolar affective disorder 7 (6.31)
F32 Depressive episode 1 (0.90)
F71 Moderate mental retardation 9 (8.11)
F72 Severe mental retardation 4 (3.60)
G40 Epilepsy 4 (3.60)
Others 12 (10.81)
Total 111 (100)b
a AF – Absolute frequency, RF% – Relative frequency in percentage.
b It is observed that some patients have more than one mental
disorder.
Table 3 – Therapeutic classes of psychotropic drugs used
by patients attended at CAPS Valter Correia, according to
ATC classiﬁcation.
ATC Therapeutic class AF (RF%)*
N03A ANTIEPILEPTICS 26 (9.63)
N03AA Barbiturates and derivatives 12 (4.44)
N03AB Hydantoin derivatives 2 (0.74)
N03AE Benzodiazepine derivatives 8 (2.96)
N03AF Carboxamide derivatives 16 (5.93)
N04A ANTICHOLINERGIC AGENTS 18 (6.67)
N04AA Tertiary amines 18 (6.67)
N05A ANTIPSYCHOTICS 121 (44.81)
N05AA Phenothiazines with aliphatic
side-chain
46  (17.04)
N05AC Phenothiazines with piperidine
structure
6  (2.22)
N05AD Butyrophenone derivatives 65 (24.07)
N05AN Lithium 2 (0.74)
N05AX Other antipsychotics 2 (0.74)
N05B ANXIOLYTICS 22 (8.15)
N05BA Benzodiazepine derivatives 22 (8.15)
N06A ANTIDEPRESSANTS 23 (8.52)
N06AA Non-selective monoamine
reuptake inhibitors
16  (5.93)
N06AB Selective serotonin reuptake
inhibitors
7  (2.59)
R06A ANTIHISTAMINES FOR SYSTEMIC
USE
43  (15.93)
R06AD Phenothiazine derivatives 43 (15.93)
V03A ALL OTHER THERAPEUTIC
PRODUCTS
5  (1.85)
V03AA Drugs for treatment of chronic
alcoholism
5  (1.85)
Total 219 (100)
∗ AF – Absolute frequency, RF% – Relative frequency in percentage.
Table 4 – Therapeutic classes of non-psychotropic drugs
used by patients attended at CAPS Valter Correia,
according to ATC classiﬁcation.
ATC Therapeutic class AF (RF%)*
A02B Drugs for treatment of peptic ulcer 3 (7.89)
A04A Antiemetics and antinauseants 2 (5.26)
A06A Laxatives 2 (5.26)
A07D Antipropulsives 1 (2.63)
A10B Oral blood glucose lowering drugs 1 (2.63)
B03A Iron preparations 1 (2.63)
B03B Vitamin B12 and folic acid 2 (5.26)
C01D Vasodilators used in cardiac
diseases
1  (2.63)
C02A Antiadrenergic agents, centrally
acting
1  (2.63)
C03A Low-ceiling diuretics, thiazides 1 (2.63)
C03C High-ceiling diuretics 1 (2.63)
C07A Beta blocking agents 3 (7.89)
C09A Ace inhibitors, plain 6 (15.79)
C09C Angiotensin II antagonists, plain 1 (2.63)
G03A Hormonal contraceptives
for systemic use
1  (2.63)
G03G Gonadotropins and other
ovulation stimulants
1  (2.63)
G04B Other urologicals, incl.
antispasmodics
1  (2.63)
H02A Corticosteroids for systemic use,
plain
1  (2.63)
M03A Muscle relaxants, peripherally
acting agents
3  (7.89)
R03A Adrenergics, inhalants 1 (2.63)
R03C Adrenergics for systemic use 1 (2.63)
R03D Other anti-asthmatics for systemic
use
1  (2.63)
R05C Expectorants, excl. combinations
with cough suppressants
1  (2.63)
R06A Antihistamines for systemic use 1 (2.63)
Total 38 (100)∗ AF – Absolute frequency, RF% – Relative frequency in percentage.
The average number of medications (psychotropic and
non-psychotropic) used by patients was 3.11 ± 1.41 medica-
tions/patients, median 3 (Table 5).
Table 6 shows the percentage of drug interactions pre-
sented by pacients of the CAPS, according to the degree of
severity.
With respect to consumption of others substances, it is
observed in Table 7 the proﬁle of use alcohol, tobacco, illicit
drugs and teas.
Discussion
The CAPS is an open and community service of mental health
on the uniﬁed health system (SUS) in Brazil. Its main objective
is to establish a reference place to treatment for people with
mental disorders, who need an intensive care related to their
severity and/or persistence demand.5
101 registered patients at CAPS ‘Valter Correia’ were dis-
tributed in intensive (13.86%), semi-intensive (52.48%) and
non-intensive (33.66%) regime. The average age of patients
was 42.18 ± 12.01 years. These results were in concordance by
r e v p o r t s a ú d e p ú b l i c a
Table 5 – Mean number of medications (psychotropic
and non-psychotropic) used by patients attended at
CAPS Valter Correia, according to the age group.
Age group (years) Average amount of
medications used/patient
20–24 2.33 ± 1.21
25–29 3.89 ± 1.17
30–34 2.82 ± 1.01
35–39 2.62 ± 0.96
40–44 2.91 ± 1.20
45–49 2.70 ± 1.42
50–54 3.88 ± 1.96
55–59 3.50 ± 0.71
60–64 3.00 ± 0.71
65–69 3.00 ± 0.00
70–74 3.00 ± 0.00
75–80 5.50 ± 0.00
Values are expressed as mean ± standard deviation.
Table 6 – Drug interactions (drug–drug) presented by
patients attended at CAPS Valter Correia, classiﬁed by
degreed severity.
Type of interaction AF (RF%)*
Light 4  (3.01%)
Moderate 72 (54.13%)
Several 39 (29.32%)
Contraindicated 18 (13.54%)
Totaly 133 (100%)
∗ AF – Absolute frequency, RF% – Relative frequency in percentage.
Table 7 – Consume of alcohol, tobacco, coffee, illicit drugs
and tea by patients attended at CAPS Valter Correia.
Substances Consume AF (RF%)*
Alcohol <2  cups/week 1 (0.99)
>6 cups/week 18 (17.82)
2–6 cups/week 4 (3.96)
Sporadically 1 (0.99)
Do not consume 76 (75.25)
Trying to stop 1 (0.99)
Tobacco <1 wallet/day 15 (14.85)
>1 wallet/day 23 (22.77)
Does not consume 63 (62.38)
Coffee <2 cup/day 17 (16.83)
>6 cups/day 8 (7.92)
2–6 cups/day 20 (19.80)
Sporadically 36 (35.64)
History of dependence 5 (4.95)
Do not consume 14 (13.86)
Trying to stop 1 (0.99)
Illicit
drugs
>6 times/week 1 (0.99)
2–6 times/week 1 (0.99)
Sporadically 2 (1.98)
History of dependence 2 (1.98)
Do not consume 95 (94.06)
Tea <2 cups/day 10 (9.90)
>2 cups/day 9 (8.91)
Sporadically 46 (45.54)
Do not consume 36 (35.64)
∗ AF – Absolute frequence, RF% – Relative frequency in percentage. . 2 0 1 2;3 0(1):55–61 59
other studies, which claim that mental disorders affect people
of all ages, with the prevalence on 30–49 years.24,25 The pres-
ence of mental disorder at this age group inﬂuences the way
of life, interrupting productivity as a result of disability caused
by disease.24
It is observed in Table 1 that the CAPS consisted mainly
of male patients (58.50%), which differs from others studies
that indicate the prevalence of females.24,26
Most patients were single (76.20%), childless (54.50%), illit-
erate (51.50%), without occupation (90.10%), without beneﬁts
(49.50%) and without monthly income (49.50%). These results
suggest that the presence of mental disorder can inﬂuence the
cultural background of people and the chance to attend school
is low, which can make it difﬁcult to enter at university and
gain a good job. According to OMS (2001)2, ﬁve from ten causes
of inability on the world are mental disorder.
Regarding to the nosological proﬁles, Table 2 reveals that
there are patients with more  than one type of mental disorder
and that schizophrenia is the most prevalent mental disorder
(31.53%).
Schizophrenia is one of the most serious neuropsychiatric
diseases and affects about 1% of world population. Currently,
there is no speciﬁc prevention for this disease. Neuroleptic or
antipsychotic drugs are used as the primary treatment for all
stages of the disease.27
Depressive episodes are common mental disorders on
Brazilian population,28–31 but we found in only 0.90% of our
CAPS patients. This difference should be caused due to the
introduction of a new model of psychiatric care, which is
still suffering transition in Brazil. Part of the population,
who suffers from mood and anxiety disorders, is probably
under-diagnozed. Another part, even receiving the correct
medical diagnosis, chooses to receive ambulatory treatment
without resort to the CAPS, which could be in consequence of
stigmas fear.
Consumption of alcohol and others drugs is an impor-
tant cause of disorder. Mental behavioral disorders due
the consumption of alcohol were found in 18.02%, due the
consumption of multiple drugs and others psychoactive sub-
stances in 0.90% and due to the use of cocaine in 0.90%. Those
patients should be indicated for an AD type of CAPS.
The psychiatric drug class most frequently prescribed was
antipsychotics (44.8%), described in Table 3. Angiotensin-
converting enzyme inhibitors (ACEI) were the most prevalent
non-psychiatric drug class (15.8%) (Table 4). Those results
are in consistence with the most prevalent diseases,
schizophrenia for antipsychotics and hypertension for ACEI
medications.
There is currently a very large number of antipsychotic
medications, with different proﬁle of side effects, but with
similar potency when use in equivalent doses. However, there
are individual differences on efﬁcacy, tolerance and cost. Par-
ticular context should be used to choose the adequate drug.
The average number of medications used by patients was
3.11 ± 1.41 medications/patients. The largest consumption of
medications was found in the 75–80 years group, 5.5 medica-
tions for patient (Table 5). These data are in with the literature.
Elderly population is marked by a higher frequency of chronic
degenerative diseases. It has greater demand for health
services and medication, which predisposes the geriatric
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population to great risks with the practice of polypharmacy
and adverse effects of medications.32
In regard to drug interactions,33–35 3.0% mild, 54.1% mod-
erate, 29.3% severe and 13.5% contraindicated (Table 6). Those
results demonstrate the need to evaluate possible inter-
ventions, since drug interactions may, among other things,
increase undesired medications effects, lead to ineffective
therapy and endanger the life of patient.36–39
It is observed in Table 7 that 24.75% of patients consumed
alcohol, 37.62% tobacco, 86.14% caffeine, 5.94% illicit drugs
and 64.36% tea. It is necessary a further detailed study, since
these substances can interact with several medications.
The medications have an important role in the health sys-
tem, they can save lives or remove the signs and symptoms
of numerous diseases.40 However, the drugs may increase the
costs of health care if used improperly.41 According to WHO
data, hospitals spend 15%–20% of their budgets to deal with
the complications caused by misuse of medications.42
In this context, pharmacists are professionals who can
actively participate in the multidisciplinary team, make the
management of pharmacotherapy, assess the use of medica-
tions, provide guidelines and perform pharmacotherapeutic
monitoring of patients, which contribute to the rational use of
medications and improve the quality of life of patients.43
Conclusion
Our results revealed the need for monitoring the pharma-
cotherapy of patients with mental and behavioral disorders to
encourage the rational use of medications. This monitoring is
necessary, since these patients are polymedicated, have other
comorbidities, and use drugs that cause adverse effects, which
compromise the adherence of treatment and consequently
their quality of life.
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